A comprehensive analysis of intracranial chordoma and survival

A systematic review

Brian J. Jian, Orin G. Bloch, Isaac Yang, Seunggu (Jude) Han, Derrick Aranda, Andrew T. Parsa

Research output: Contribution to journalReview article

38 Citations (Scopus)

Abstract

Objective. Despite the published information on cranial chordoma, most of the data regarding survival in these patients has come from a single institution. Here, we perform a systematic review of the literature to evaluate across multiple institutions the overall survival after treatment for intracranial chordoma. Materials and methods. We systematically analysed every study published in English and found a total of over 2000 patients being treated for intracranial chordoma. The overall 5-year and 10-year survivals in these patients were stratified according to the age (<5 years vs. >5 years and <40 years vs. >40 years), treatment (surgery and radiation vs. surgery alone) and histological findings (chondroid vs. typical). Data were analysed via Pearson chi-square test and student t-test when appropriate. Results. A total of 560 non-duplicated patients treated for cranial chordoma met inclusion criteria for this systematic analysis. The survival rate among these patients was 63% (299 patients) and 16% (176 patients) for 5-year and 10-year survivals, respectively. There was no difference in overall survival between the two groups when a cut-off age of 40 years was used (<40 years = 50% vs. >40 years = 51% at 5-year survival; p = 0.1), but when 5 years was used as the cut-off age, then survival was better for patients in the group older than 5 years of age (<5 years = 14% vs. >5 years = 66%; p = 0.001). There was no difference between 5-year survival in patients with chordoma with histological chondroid features and those with chordoma possessing typical histology (45% vs. 67%; p = 0.06). When patients who only received surgery were compared to those patients who were treated with surgical intervention in combination with adjuvant radiation treatment, no difference in survival rate was found (54% vs. 56% at 5 years; p = 0.8). Conclusion. The results of our systematic study provide data to predict the survival of intracranial chordoma patients across multiple institutions. Our data suggest that patients younger than 5 years of age may be associated with a worse prognosis, and adjuvant radiation therapy and histological type were not associated with the improvement of survival rates.

Original languageEnglish (US)
Pages (from-to)446-453
Number of pages8
JournalBritish Journal of Neurosurgery
Volume25
Issue number4
DOIs
StatePublished - Aug 1 2011
Externally publishedYes

Fingerprint

Chordoma
Survival
Survival Rate
Radiation
Chi-Square Distribution

Keywords

  • age
  • histologic subtype
  • Intracranial chordoma
  • survival
  • systematic review
  • treatment

ASJC Scopus subject areas

  • Surgery
  • Clinical Neurology

Cite this

A comprehensive analysis of intracranial chordoma and survival : A systematic review. / Jian, Brian J.; Bloch, Orin G.; Yang, Isaac; Han, Seunggu (Jude); Aranda, Derrick; Parsa, Andrew T.

In: British Journal of Neurosurgery, Vol. 25, No. 4, 01.08.2011, p. 446-453.

Research output: Contribution to journalReview article

Jian, Brian J. ; Bloch, Orin G. ; Yang, Isaac ; Han, Seunggu (Jude) ; Aranda, Derrick ; Parsa, Andrew T. / A comprehensive analysis of intracranial chordoma and survival : A systematic review. In: British Journal of Neurosurgery. 2011 ; Vol. 25, No. 4. pp. 446-453.
@article{2ac4bb0e3f8541a4a1eb082ba591b3e9,
title = "A comprehensive analysis of intracranial chordoma and survival: A systematic review",
abstract = "Objective. Despite the published information on cranial chordoma, most of the data regarding survival in these patients has come from a single institution. Here, we perform a systematic review of the literature to evaluate across multiple institutions the overall survival after treatment for intracranial chordoma. Materials and methods. We systematically analysed every study published in English and found a total of over 2000 patients being treated for intracranial chordoma. The overall 5-year and 10-year survivals in these patients were stratified according to the age (<5 years vs. >5 years and <40 years vs. >40 years), treatment (surgery and radiation vs. surgery alone) and histological findings (chondroid vs. typical). Data were analysed via Pearson chi-square test and student t-test when appropriate. Results. A total of 560 non-duplicated patients treated for cranial chordoma met inclusion criteria for this systematic analysis. The survival rate among these patients was 63{\%} (299 patients) and 16{\%} (176 patients) for 5-year and 10-year survivals, respectively. There was no difference in overall survival between the two groups when a cut-off age of 40 years was used (<40 years = 50{\%} vs. >40 years = 51{\%} at 5-year survival; p = 0.1), but when 5 years was used as the cut-off age, then survival was better for patients in the group older than 5 years of age (<5 years = 14{\%} vs. >5 years = 66{\%}; p = 0.001). There was no difference between 5-year survival in patients with chordoma with histological chondroid features and those with chordoma possessing typical histology (45{\%} vs. 67{\%}; p = 0.06). When patients who only received surgery were compared to those patients who were treated with surgical intervention in combination with adjuvant radiation treatment, no difference in survival rate was found (54{\%} vs. 56{\%} at 5 years; p = 0.8). Conclusion. The results of our systematic study provide data to predict the survival of intracranial chordoma patients across multiple institutions. Our data suggest that patients younger than 5 years of age may be associated with a worse prognosis, and adjuvant radiation therapy and histological type were not associated with the improvement of survival rates.",
keywords = "age, histologic subtype, Intracranial chordoma, survival, systematic review, treatment",
author = "Jian, {Brian J.} and Bloch, {Orin G.} and Isaac Yang and Han, {Seunggu (Jude)} and Derrick Aranda and Parsa, {Andrew T.}",
year = "2011",
month = "8",
day = "1",
doi = "10.3109/02688697.2010.546896",
language = "English (US)",
volume = "25",
pages = "446--453",
journal = "British Journal of Neurosurgery",
issn = "0268-8697",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - A comprehensive analysis of intracranial chordoma and survival

T2 - A systematic review

AU - Jian, Brian J.

AU - Bloch, Orin G.

AU - Yang, Isaac

AU - Han, Seunggu (Jude)

AU - Aranda, Derrick

AU - Parsa, Andrew T.

PY - 2011/8/1

Y1 - 2011/8/1

N2 - Objective. Despite the published information on cranial chordoma, most of the data regarding survival in these patients has come from a single institution. Here, we perform a systematic review of the literature to evaluate across multiple institutions the overall survival after treatment for intracranial chordoma. Materials and methods. We systematically analysed every study published in English and found a total of over 2000 patients being treated for intracranial chordoma. The overall 5-year and 10-year survivals in these patients were stratified according to the age (<5 years vs. >5 years and <40 years vs. >40 years), treatment (surgery and radiation vs. surgery alone) and histological findings (chondroid vs. typical). Data were analysed via Pearson chi-square test and student t-test when appropriate. Results. A total of 560 non-duplicated patients treated for cranial chordoma met inclusion criteria for this systematic analysis. The survival rate among these patients was 63% (299 patients) and 16% (176 patients) for 5-year and 10-year survivals, respectively. There was no difference in overall survival between the two groups when a cut-off age of 40 years was used (<40 years = 50% vs. >40 years = 51% at 5-year survival; p = 0.1), but when 5 years was used as the cut-off age, then survival was better for patients in the group older than 5 years of age (<5 years = 14% vs. >5 years = 66%; p = 0.001). There was no difference between 5-year survival in patients with chordoma with histological chondroid features and those with chordoma possessing typical histology (45% vs. 67%; p = 0.06). When patients who only received surgery were compared to those patients who were treated with surgical intervention in combination with adjuvant radiation treatment, no difference in survival rate was found (54% vs. 56% at 5 years; p = 0.8). Conclusion. The results of our systematic study provide data to predict the survival of intracranial chordoma patients across multiple institutions. Our data suggest that patients younger than 5 years of age may be associated with a worse prognosis, and adjuvant radiation therapy and histological type were not associated with the improvement of survival rates.

AB - Objective. Despite the published information on cranial chordoma, most of the data regarding survival in these patients has come from a single institution. Here, we perform a systematic review of the literature to evaluate across multiple institutions the overall survival after treatment for intracranial chordoma. Materials and methods. We systematically analysed every study published in English and found a total of over 2000 patients being treated for intracranial chordoma. The overall 5-year and 10-year survivals in these patients were stratified according to the age (<5 years vs. >5 years and <40 years vs. >40 years), treatment (surgery and radiation vs. surgery alone) and histological findings (chondroid vs. typical). Data were analysed via Pearson chi-square test and student t-test when appropriate. Results. A total of 560 non-duplicated patients treated for cranial chordoma met inclusion criteria for this systematic analysis. The survival rate among these patients was 63% (299 patients) and 16% (176 patients) for 5-year and 10-year survivals, respectively. There was no difference in overall survival between the two groups when a cut-off age of 40 years was used (<40 years = 50% vs. >40 years = 51% at 5-year survival; p = 0.1), but when 5 years was used as the cut-off age, then survival was better for patients in the group older than 5 years of age (<5 years = 14% vs. >5 years = 66%; p = 0.001). There was no difference between 5-year survival in patients with chordoma with histological chondroid features and those with chordoma possessing typical histology (45% vs. 67%; p = 0.06). When patients who only received surgery were compared to those patients who were treated with surgical intervention in combination with adjuvant radiation treatment, no difference in survival rate was found (54% vs. 56% at 5 years; p = 0.8). Conclusion. The results of our systematic study provide data to predict the survival of intracranial chordoma patients across multiple institutions. Our data suggest that patients younger than 5 years of age may be associated with a worse prognosis, and adjuvant radiation therapy and histological type were not associated with the improvement of survival rates.

KW - age

KW - histologic subtype

KW - Intracranial chordoma

KW - survival

KW - systematic review

KW - treatment

UR - http://www.scopus.com/inward/record.url?scp=79961203303&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79961203303&partnerID=8YFLogxK

U2 - 10.3109/02688697.2010.546896

DO - 10.3109/02688697.2010.546896

M3 - Review article

VL - 25

SP - 446

EP - 453

JO - British Journal of Neurosurgery

JF - British Journal of Neurosurgery

SN - 0268-8697

IS - 4

ER -